Abstract
In response to environmental cues that promote IP3 (inositol 1,4,5-trisphosphate) generation, IP3 receptors (IP3Rs) located on the endoplasmic reticulum allow the ‘quasisynaptical’ feeding of calcium to the mitochondria to promote oxidative phosphorylation1. However, persistent Ca2+ release results in mitochondrial Ca2+ overload and consequent apoptosis2. Among the three mammalian IP3Rs, IP3R3 appears to be the major player in Ca2+-dependent apoptosis. Here we show that the F-box protein FBXL2 (the receptor subunit of one of 69 human SCF (SKP1, CUL1, F-box protein) ubiquitin ligase complexes3) binds IP3R3 and targets it for ubiquitin-, p97- and proteasome-mediated degradation to limit Ca2+ influx into mitochondria. FBXL2-knockdown cells and FBXL2-insensitive IP3R3 mutant knock-in clones display increased cytosolic Ca2+ release from the endoplasmic reticulum and sensitization to Ca2+-dependent apoptotic stimuli. The phosphatase and tensin homologue (PTEN) gene is frequently mutated or lost in human tumours and syndromes that predispose individuals to cancer4. We found that PTEN competes with FBXL2 for IP3R3 binding, and the FBXL2-dependent degradation of IP3R3 is accelerated in Pten−/− mouse embryonic fibroblasts and PTEN-null cancer cells. Reconstitution of PTEN-null cells with either wild-type PTEN or a catalytically dead mutant stabilizes IP3R3 and induces persistent Ca2+ mobilization and apoptosis. IP3R3 and PTEN protein levels directly correlate in human prostate cancer. Both in cell culture and xenograft models, a non-degradable IP3R3 mutant sensitizes tumour cells with low or no PTEN expression to photodynamic therapy, which is based on the ability of photosensitizer drugs to cause Ca2+-dependent cytotoxicity after irradiation with visible light5,6. Similarly, disruption of FBXL2 localization with GGTi-2418, a geranylgeranyl transferase inhibitor7, sensitizes xenotransplanted tumours to photodynamic therapy. In summary, we identify a novel molecular mechanism that limits mitochondrial Ca2+ overload to prevent cell death. Notably, we provide proof-of-principle that inhibiting IP3R3 degradation in PTEN-deregulated cancers represents a valid therapeutic strategy.
To identify FBXL2 substrates, FBXL2 was expressed in HEK293T cells, immunopurified and analysed for co-purifying proteins by mass spectrometry, which revealed the presence of two unique peptides corresponding to IP3R3. To confirm these results, we screened a panel of human F-box proteins and found that the only F-box protein that co-immunoprecipitated IP3R3 was FBXL2 (Extended Data Fig. 1a). FBXL2 co-immunoprecipitated SKP1, CUL1 and IP3R3 from the membrane fraction (Extended Data Fig. 1b). FBXL2 contains a C-terminal CaaX domain that is required for its geranylgeranylation and localization at cell membranes8. In contrast to wild-type FBXL2, FBXL2(CaaX/SaaX), a geranylgeranylation-deficient mutant in which a cysteine in the CaaX domain has been mutated to serine9, did not fractionate with cellular membranes and did not interact with IP3R3 and neddylated CUL1 (Extended Data Fig. 1c, d).
We also observed that expression of wild-type FBXL2, but not FBXL2(ΔF-box), an inactive mutant, induced a decrease in the levels of IP3R3 (this decrease was rescued by MG132 treatment) and FBXL2(ΔF-box) bound more IP3R3 than wild-type FBXL2 (this difference was abolished by MG132 treatment) (Extended Data Fig. 1d, e).
Since IP3-mediated Ca2+ release is stimulated by mitogens, we examined the impact of serum on IP3R3 levels. The growth of normal human fibroblasts (NHFs) was arrested by serum deprivation after which serum was reintroduced. The levels of IP3R3 decreased in control cells, but much less in cells treated with MG132 or lactacystin, or in which FBXL2 was silenced (Extended Data Fig. 1f–i). In hTERT RPE-1 cells, elimination of one FBXL2 allele resulted in IP3R3 stabilization (Extended Data Fig. 1j–l). GGTi-2418 treatment delocalized FBXL2 and stabilized IP3R3 (Extended Data Fig. 2a–c). Eer1, an inhibitor of p97 (also known as VCP or Cdc48), a segregase that extracts ubiquitinated proteins from the cellular membranes to facilitate their proteasomal degradation10, blocked IP3R3 degradation (Extended Data Fig. 2d). Silencing of p97 inhibited the serum-mediated degradation of IP3R3, and both FBXL2 and IP3R3 co-immunoprecipitated with p97 (Extended Data Fig. 2e, f). Finally, immunopurified FBXL2, but not FBXL2(ΔF-box), promoted the in vitro ubiquitination of IP3R3 (Extended Data Fig. 2g, h).
To investigate the role of FBXL2 in Ca2+ homeostasis, we measured the changes in Ca2+ concentration in both the cytosol and mitochondria of NHFs in response to ATP, a purinergic GPCR agonist that induces IP3 production and rapid flow of Ca2+ from the endoplasmic reticulum to the mitochondria11. Serum starvation caused an increase and serum re-addition induced a decrease in Ca2+ mobilization (Fig. 1a and Extended Data Fig. 3a). FBXL2 silencing or treatment with MG132 or GGTi-2418 inhibited the serum-mediated decrease in Ca2+ mobilization (Fig. 1a and Extended Data Fig. 3b, c). Conversely, cells engineered to express FBXL2, but not FBXL2(CaaX/SaaX), displayed low IP3R3 levels and a decrease in Ca2+ mobilization (Extended Data Figs 1c and 3d, e).
Serum starvation sensitized NHFs to treatment with H2O2, an oxidizing agent that induces persistent release of Ca2+ from the endoplasmic reticulum and consequent apoptosis, but serum re-addition alleviated this sensitivity (Fig. 1b). Compared to cells re-stimulated with serum, serum-starved cells displayed an increase in cleaved PARP, cleaved caspase-3, and cytochrome c release (Fig. 1c, d), all signatures of apoptosis. In cells re-stimulated with serum, FBXL2 knockdown caused IP3R3 accumulation (Extended Data Fig. 1h, i), sensitization to H2O2, and an increase in the apoptotic signature and in mitochondrial Ca2+ uptake (Fig. 1b–d and Extended Data Fig. 3f). Conversely, expression of wild-type FBXL2, but not FBXL2(CaaX/SaaX), induced resistance to H2O2, but not to etoposide (Extended Data Fig. 3g). Inhibition of mitochondrial Ca2+ overload by silencing MCUA (mitochondrial calcium uniporter, isoform a) or preventing the PTP opening using cyclosporin-A abolished the sensitization to H2O2 by FBXL2 silencing (Fig. 1b).
Next, we mapped the FBXL2 binding domain (that is, the degron) in IP3R3 and narrowed it to a region located between amino acids 436– 587 (Extended Data Fig. 4a, b). Fragments encoding IP3R3(436–587) and IP3R3(227–602) interacted with FBXL2 more stably than IP3R3 (1–602), suggesting that the N-terminal suppressor domain of IP3R3 inhibits the FBXL2–IP3R3 interaction. Treatment of cells with ATP, which induces IP3 production and repositioning of the N-terminal suppressor domain11, increased the binding between FBXL2 and IP3R3, particularly upon proteasome inhibition (Extended Data Fig. 4c, d). This suggests that once IP3 unmasks the IP3R3 degron, FBXL2 binds IP3R3 and this interaction is maintained, particularly if the degradation of IP3R3 is inhibited. Finally, ATP promoted the degradation of IP3R3 in cells cultured in the presence, but not in the absence, of serum (Extended Data Fig. 4e).
We then fine-mapped the degron to a region between amino acids 545 and 566 and found that Phe553 (which is highly conserved in IP3R3 orthologues, but not in its paralogues), and to a lesser extent Gln550 and Arg554, were necessary for efficient binding of IP3R3 to FBXL2 (Extended Data Fig. 4f–i). IP3R3(Q-FR/A-AA), a mutant in which Gln550, Phe553 and Arg554 were mutated to Ala, displayed a longer half-life than wild-type IP3R3, and it was not degraded when serum-starved cells were re-stimulated with serum (Fig. 1e, f). Expression of FBXL2 resulted in increased ubiquitination of IP3R3, but IP3R3(Q-FR/A-AA) remained poorly ubiquitinated (Extended Data Fig. 4j).
Importantly, expression of IP3R3(Q-FR/A-AA) recapitulated the phenotypes observed upon FBXL2 silencing: enhanced Ca2+ release from the endoplasmic reticulum following serum treatment and agonist stimulation, and sensitization to H2O2 (Fig. 1g–i and Extended Data Fig. 3h, i). Moreover, in cells expressing IP3R3(Q-FR/A-AA), MG132 did not produce an increase of the Ca2+ response (Fig. 1g and Extended Data Fig. 3h).
Certain tumour suppressors and oncoproteins with roles in Ca2+ homeostasis localize to the endoplasmic reticulum (for example, AKT1, BCL2, p53, PML4, PTEN and KRAS4B)12. When these six proteins were expressed in HEK293T cells, PTEN was the only one able to robustly interact with endogenous IP3R3, and the interaction between PTEN and IP3R3 was confirmed at the endogenous level (Extended Data Fig. 5a–c). Compared to Pten+/+ mouse embryonic fibroblasts (MEFs)13, the steady-state levels of IP3R3 were lower and its half-life was shorter in Pten−/− MEFs (Extended Data Fig. 5d, e). Importantly, in response to mitogens, IP3R3 was degraded faster in Pten−/− than in Pten+/+ MEFs, and this phenotype was reverted by silencing FBXL2 (Fig. 2a). Finally, after serum re-addition, IP3R3 was ubiquitinated to a greater extent in Pten−/− than in Pten+/+ MEFs (Extended Data Fig. 5f).
PTEN reconstitution in Pten−/− MEFs and cell lines expressing no or low levels of PTEN induced an increase in the levels of IP3R3 (Fig. 2b and Extended Data Fig. 5g). PTEN(C124S), a catalytically dead mutant4, was also able to enhance IP3R3 levels and induce apoptotic cleavage of caspase-3, although not as efficiently as wild-type PTEN, (Fig. 2b and Extended Data Fig. 5g). Silencing of IP3R3 counteracted the apoptotic cleavage of caspase-3 induced by PTEN(C124S) (Fig. 2b). Expression of wild-type PTEN or, to a lesser extent, PTEN(C124S) in Pten−/− MEFs augmented Ca2+ mobilization from the endoplasmic reticulum in an IP3R3-dependent manner (Fig. 2c and Extended Data Fig. 5h). PTEN(G129E), a mutant displaying a greatly reduced lipid phosphatase activity, but retaining protein phosphatase activity4, induced an increase in the Ca2+ response identical to that induced by wild-type PTEN (Fig. 2c and Extended Data Fig. 5h). Finally, PTEN, PTEN(C124S) and PTEN(G129E) bound comparable amounts of IP3R3 (Extended Data Fig. 5i).
Like FBXL2, PTEN interacted more stably with IP3R3(436–587) and accordingly IP3R3(Q-FR/A-AA), which is impaired in its binding to FBXL2, interacted less with PTEN (Extended Data Fig. 6a, b), suggesting that PTEN and FBXL2 compete for the same region in IP3R3. Indeed, increasing amounts of FBXL2 interfered with the binding between PTEN and IP3R3, and increasing amounts of PTEN interfered with the binding between FBXL2 and IP3R3 (Extended Data Fig. 6c–e). Conversely, PTEN silencing, in addition to reducing IP3R3 levels, resulted in an increased interaction between IP3R3 and FBXL2 (Extended Data Fig. 6f).
Compared to cells expressing PTEN, IP3R3 levels were significantly lower in cell lines expressing no or low levels of PTEN, although all cell lines expressed similar levels of FBXL2 mRNA (Extended Data Fig. 6g, h). The half-life of IP3R3 was significantly shorter in A549 cells compared to H460 (the former expressing low PTEN levels), and IP3R3 levels increased in U87 and A549 cells after reconstitution of PTEN expression or upon FBXL2 inhibition by GGTi-2418 (Extended Data Figs 5g and 6i, j). We also assessed the expression of PTEN and IP3R3 in tissue microarrays generated from human prostate adenocarcinomas and found that there was a significant, direct correlation between IP3R3 and PTEN expression levels (Fig. 2d and Extended Data Fig. 6k).
PDT-induced Ca2+ mobilization was significantly reduced when PTEN or IP3R3 were depleted, and, compared to cell lines expressing PTEN and high levels of IP3R3, cancer cell lines expressing no or low levels of PTEN and low levels of IP3R3 displayed less Ca2+ mobilization and less apoptotic markers upon photodynamic therapy (PDT) treatment (Extended Data Fig. 7a, b). Re-expression of either wild-type PTEN or PTEN(C124S) increased PDT-induced Ca2+ mobilization and apoptotic cleavage of caspase-3 and PARP (Extended Data Fig. 7c, d). Depletion of FBXL2 resulted in increased PDT-induced Ca2+ mobilization and apoptosis in cells with no or low levels of PTEN, which depended on the presence of IP3R3 (Fig. 3a and Extended Data Fig. 8a). Similarly, expression of IP3R3(Q-FR/A-AA) increased PDT-induced Ca2+ mobilization and apoptosis (Extended Data Fig. 8b). We also generated A549 and PC3 knock-in clones expressing IP3R3(Q-FR/A-AA) (Extended Data Fig. 9a–c). Compared to parental cells, these clones displayed the stabilization of IP3R3, released more Ca2+ from the endoplasmic reticulum, and were more prone to apoptosis when treated with PDT (Fig. 3b and Extended Data Fig. 9d–g).
We then stably transfected A549 and PC3 cells with either an empty vector or IP3R3(Q-FR/A-AA) for xenograft transplantation experiments in NOD/SCID gamma mice. These xenografts did not show any significant difference in growth curves (Fig. 4a and Extended Data Fig. 10a). However, PDT significantly reduced the tumour weight and growth rate of IP3R3(Q-FR/A-AA) expressing xenografts, whereas empty vector xenografts were unaffected (Fig. 4a and Extended Data Fig. 10a). Accordingly, in response to PDT, increased apoptosis was detected in IP3R3(Q-FR/A-AA) xenografts compared to empty vector xenografts (Fig. 4b and Extended Data Fig. 10b). Virtually identical results were obtained using a A549 knock-in clone expressing endogenous IP3R3(Q-FR/A-AA) (Extended Data Fig. 10c, d).
We also administered intratumoural injections of GGTi-2418, which has reached phase I clinical trial7, delocalizes FBXL2 from membranes, and stabilizes IP3R3 (see above). GGTi-2418, by itself, only modestly affected the growth rate of xenografts. However, GGTi-2418 significantly sensitized tumour xenografts to PDT (Fig. 4c, d).
Recent studies suggest that non-catalytic activities of PTEN contribute to its tumour suppressor function through poorly defined mechanisms. Our study reveals a phosphatase-independent mechanism by which PTEN functions as a tumour suppressor (Extended Data Fig. 10e). Moreover, we show that when IP3R3 degradation is inhibited, tumours with no or low levels of PTEN expression become sensitive to PDT. We propose that such tumours should not only be treated with inhibitors targeting the PI3K signalling cascade (which is hyperactive in these cancers), but also with drugs that result in IP3R3 stabilization, thereby abrogating both arms of PTEN function.
Methods
No statistical methods were used to predetermine sample size and the investigators were not blinded to allocation during experiments and outcome assessment.
Antibodies, reagents, and biochemical methods
Immunoprecipitation and immunoblotting experiments were performed as previously described9,14,15. In some experiments, 2–4% of whole-cell lysate inputs (depending on the protein of interest) were run together with immunoprecipitates. The following antibodies were used: IP3R1(Bethyl no. A302-157A), IP3R-2(Millipore no. AB3000), IP3R3 (BD-Pharmingen no. 610312), PTEN (Cell Signaling Technology no. 9559S), calnexin (Santa Cruz no. sc11397), cleaved PARP (Cell Signaling Technology no. 5625S), cleaved caspase-3 (Cell Signaling Technology #9661S), cytochrome c (BD no. 556433), AKT (Cell Signaling Technology no. 2920S), pAKT-S473 (Cell Signaling Technology no. 4058S), p97 (Thermo Scientific no. PA5-22257), p85|3 (AbCam no. ab28356), GFP (Cell Signaling Technology no. 2956S), CUL1 (Invitrogen no. 718700), SKP1 (generated in-house), Flag (Sigma), HA (Covance), α-tubulin (Sigma), and β-actin (Sigma). Isotype-specific horseradish peroxidase conjugated secondary antibodies were used for detection by enhanced chemiluminescence (Pierce). All cDNA constructs were N-terminally tagged either with Flag, HA, GFP or GST (specific details provided on request).
Cell culture and transfections
Cell lines and primary fibroblasts were purchased from ATCC, except where indicated. All cell lines were treated with Plasmocin and tested with Universal Mycoplasma Detection Kit from ATCC. NHFs were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS. MEFs (Pten+/+ and Pten−/−, provided by R. Parsons' laboratory)13, HeLa, and COS-7 cells (African Green Monkey SV40-transformed kidney fibroblasts) were grown in DMEM supplemented with 10% FBS and transfected as described9. All cells grown in culture were periodically monitored for mycoplasma contamination. Cells were starved for the indicated time periods in 0.1% FBS. Cells were serum-stimulated with DMEM supplemented with 10% FBS. Where indicated, cells were treated with 10 μM MG132 (Peptides International), 100 μM cycloheximide (Sigma), 10-15 μM GGTi-2418 (Moffit Cancer Center), 10 μM Eeyarestatin 1 (Eer1, TOCRIS bioscience), 100 μM histamine (Sigma), 10 μM MRS2578 (Sigma), 100 μM ATP (Sigma), and 1 μM cyclosporin-A (Sigma).
Tandem affinity purification and mass spectrometry
HEK293T cells were transiently transfected with Flag-HA-tagged FBXL2 or control plasmids using polyethylenimine (PEI). Twenty-four hours after transfection, cells were treated with MG132 (10 μM) for 3 h before harvesting. Immunoprecipitation and subsequent mass spectrometry was carried out as previously described9,14,15. The original mass spectrometry data can be accessed through the Stowers Original Data Repository at ftp://odr.stowers.org/LIBPB-484.
Gene silencing
For gene silencing, cells were seeded approximately 24 h before transfection. The following ON-TARGETplus siRNA oligos from Dharmacon were transfected (5–15 nM) with HiPerfect for 24–48 h, according to the manufacturer's instructions (Qiagen): ON-TARGETplus human FBXL2 (oligo 1 GCACAGAACUGCCGAAACA, oligo 2 GCUCGGAAUUGCCACGAAU, oligo 3 J-0113562-07-0005); ON-TARGETplus human ITPR3 (L-006209-00-0005); ON-TARGETplus mouse ITPR3 (L-065715-01-0005) siRNA, ON-TARGETplus mouse PTEN (L-040700-02-0005); ON-TARGETplus human PTEN (L-003023-00-0005); and ON-TARGET non-targeting siRNA 1 (D-001810-01-05). To validate gene silencing by RT–PCR, total RNA was isolated using Qiagen's RNeasy kit (cat. no. 74104). The reverse transcription reaction was carried out in triplicate using 5 μg of total RNA using Oligo-dT primers with Superscript III RT polymerase (Invitrogen) according to the manufacturer's instructions. The real-time qPCR reaction was carried out using 250 ng cDNA using SYBR Green method with Roche Light Cycler 480II machine in a 96-well format. Data were analysed using 2nd derivative maximum with high confidence software for RT values according to the manufacturer's guidelines (Roche). Bar graphs represent the relative ratio of FBXL2 to GAPDH values. The following RT-primers were used: human FBXL2, forward: 5′-ATTTGACTGACGCAGGTTT-3′, reverse: 5′-GAGCTG GATGAGTGTGCTGT-3′; human GAPDH, forward: 5′-TGCACCACCAACT GCTTAGC-3′, reverse: 5′-GGCATGGACTGTGGTCATGAG-3′.
Ubiquitination assays
Briefly, HEK-293T cells were co-transfected with HA- or GFP-tagged IP3R3 (either wild-type or an N-terminal fragment) and either Flag-tagged FBXL2 or an FBXL2(ΔF-box) mutant. Twenty-four hours after transfection, cells were incubated with MG132 for three hours before harvesting. FBXL2 (wild-type and mutant) was immunoprecipitated with anti-Flag M2 agarose beads (Sigma) and in vitro ubiquitination assays were carried out as previously described9,16. Flag-tagged trypsin-resistant tandem ubiquitin-binding entity (TR-TUBE), which directly binds polyubiquitin chains and protects them from proteasome-mediated degradation was used for cell-based assays, as previously described17,18.
Fura-2 measurements
The cytosolic Ca2+ response was evaluated using the fluorescent Ca2+ indicator Fura-2/AM (Thermo Fischer Scientific). In brief, cells were grown on 24-mm coverslips and incubated at 37 °C for 30 min in 1 mM Ca2+ in Krebs-Ringer buffer (KRB: 135 mM NaCl, 5 mM KCl, 1 mM MgSO4, 0.4 mM K2HPO4, 5.5 mM glucose, 20 mM HEPES) supplemented with 2.5 mM Fura-2/AM, 0.02% Pluronic F-68 (Sigma-Aldrich), and 0.1 mM sulfinpyrazone (Sigma-Aldrich). Cells were then washed and supplied with 1 mM Ca2+/KRB. Next, cells were placed in an open Leyden chamber on a 37 °C thermostated stage and exposed to 340/380 nm wavelength light using the Olympus xcellence (Olympus) multiple wavelength high-resolution fluorescence microscopy system equipped with an Hamamatsu ORCA ER CCD camera (Hamamatsu Photonics) and a Upl FLN 40× oil objective (Olympus) to determine the cytosolic Ca2+ response. The photo-activation of aluminium phthalocyanine chloride was obtained using an excitation filter ET576/25 (Semrock), with 500 ms of excitation every cycle. Cytosolic Ca2+ concentration was calculated as previously described19,20.
FRET-based measurements of mitochondrial Ca2+
Single-cell measurements of mitochondrial Ca2+ were performed in A549 cells or A549 knock-in clones transfected with 4mtD3cpv (ref. 6). After 36 h, cells were imaged using a Zeiss Axiovert 200 M microscope with a cooled CCD camera (Photometrics), which was equipped with a C-apochromatic 40 × /1.2 W CORR objective and controlled by MetaFluor 7.0 software (Universal Imaging). Emission ratio imaging of the 4mtD3cpv was achieved using a 436DF20 excitation filter, a 450 nm dichroic mirror, and two emission filters (475/40 for ECFP and 535/25 for citrine) that were controlled by a Lambda 10-2 filter changer (Sutter Instruments). The acquired fluorescence images were corrected for the background. The exposure times were typically 100-200 ms, and images were collected every second per wavelength. The photo-activation of aluminium phthalocyanine chloride was achieved using an excitation filter ET650/50 (Chroma Technology) with 500 ms of excitation every FRET ratio cycle.
Aequorin measurements
Cells were transfected with the mtAEQ chimaera alone or together with constructs expressing FBXL2 or IP3R3. All aequorin measurements were carried out in KRB buffer supplemented with 1 mM CaCl2. Agonists and other drugs were added to the same medium, as specified in the figure legends. The experiments were terminated by lysing cells with 100 μM digitonin in a hypotonic Ca2+-rich solution (10 mM CaCl2), thus discharging the remaining aequorin pool. The light signal was collected and calibrated into [Ca2+] values, as previously described21.
Experimental animals
Procedures involving animals and their care conformed with institutional guidelines, and all experimental protocols were approved by the animal ethics committee. NOD/SCID gamma (NSG) mice were housed in sterile conditions within high-efficiency particulate arrestance filtered micro-isolators, and fed with irradiated food and acidified water. Six-week-old male NSG mice were injected subcutaneously (s.c.) with 2 × 106 cells. When tumour mass became palpable in successfully engrafted mice (around 36 days after the injection of A549 cells and around 70 days after the injection of PC3 cells), animals were randomly divided into different groups and subjected to various treatments as indicated in the figures. Where indicated, mice were subject to two rounds of GGTi-2418 treatment (50 mg kg−1) by intratumoural injection for five consecutive days. Tumour growth was monitored daily, and tumour diameters were measured with callipers every other day. The tumour volume was calculated using the following equation: volume = π/6 × (a × b2), where a is the major diameter and b is the minor diameter. At the end of the experiment, tumour progression was confirmed by either retro-orbital or intravenous injection of fluorescently labelled IRDye 2-deoxyglucose (2-DG), which was detected 24 h after injection using a Pearl Trilogy Imaging System (Li-Cor). All mice that reached the endpoint of the experiment (60 days for A549 or 92 days for PC3 cells) were euthanized and, subsequently, tumours were excised, weighted, and either immunoblotted or sectioned for immunofluorescence.
Detection of cell death in cell systems
For cell death induction, cells were treated with different apoptotic stimuli as indicated in the text and figure legends. Apoptosis was determined by three different methods: (i) by blotting for different cell death markers, such as cleaved PARP and cleaved CASPASE-3; (ii) by analysing cytochrome c release; and (iii) by automated nuclei count analysis. For analysis of cytochrome c release, cells were fixed with 4% paraformaldehyde in PBS for 20 min, washed three times with PBS and then incubated for 10 min in PBS. Cells were then permeabilized with 0.1% Triton X-100 in PBS, followed by a 1-h wash with 2% milk in PBS. Cells were then incubated overnight at 4 °C in a wet chamber with a mouse anti-cytochrome c antibody followed by incubation with an Alexa 594 goat anti-mouse antibody and DAPI for 1 h at room temperature. After antibody incubation, cells were washed three times with PBS. Images were acquired on an Olympus ScanˆR station using a laser based autofocus and an image-based autofocus. Eighty fields were acquired for each well using a 20× magnification objective, NA 0.75. The different fluorophores were excited by an MT20 illumination system with 377/50, 595/30 excitation filters. Images were collected using an Orca-R2 CCD camera (Hamamatsu Photonics), without binning. The mean fluorescence intensities and standard deviations of nuclear cytochrome c were evaluated in comparison to corresponding controls. Automated nuclei count analysis was performed by seeding 50,000 cells on a 25-mm coverslip. Cells were grown for 48 h before treatment with H2O2 (1–2 mM for 4–16 h as indicated in figure legends) or etoposide (50 μM for 5 h). Coverslips were stained with Hoechst 10 μM, placed in an incubated chamber with controlled temperature, and mounted on a Zeiss Axiovert 200 M microscope equipped with a motorized stage. Images of nuclei (ranging in size from 5–25 μm) were acquired with a 10× Fluor objective (Zeiss) and a CoolSnap HQ CCD camera. Twenty random fields were acquired using the random stage scan tools in MetaMorph and analysed with the nuclei count application.
Detection of cell death in vivo
After a retro orbital injection of 100 μl of CAS-MAP NIR probe (Vergent Bioscience), the reagent was allowed to circulate in mice for 30 min before analysis. Fluorescent in vivo images were acquired using a Pearl Trilogy Imaging System (Li-Cor). For the analysis of apoptosis in tumour tissue sections, after a retro orbital injection of 100 μl of SR-FLIVO probe (Immunochemistry Technology), the reagent was allowed to circulate in mice for 30 min. Tumours were excised, frozen, sectioned, and stained for nuclei using DRAQ5, according to the manufacturer's protocol (Cell Signaling Technology). After staining, the samples were mounted on coverslips and analysed using a Zeiss LSM 510 confocal microscope equipped with a Fluor 40 ×/1.30 NA oil-immersion objective. The acquired images were background corrected, and signals were analysed using Fiji software (available at http://fiji.sc/Fiji).
Sub-cellular fractionation
Cells (approximately 109) were harvested, washed in phosphate-buffered saline medium, pelleted by centrifugation at 500g for 5 min, re-suspended in homogenization buffer (0.25 M sucrose and 10 mM HEPES pH 7.4) and gently disrupted by dounce homogenization. The homogenate was centrifuged twice at 600g for 5 min to remove cellular debris and nuclei, and the supernatant was centrifuged at 10,300g for 10 min to pellet crude mitochondria. The resultant supernatant was centrifuged at 100,000g for 1 h in a Beckman 70 Ti rotor at 4 °C to pellet microsomes, which were re-suspended in homogenization buffer22. The quality of the preparation was confirmed by immunoblot analysis using different markers for the fractions obtained (that is, calnexin as endoplasmic reticulum marker, and β-actin as cytosolic markers).
Immunohistochemistry in human tissue specimens
Expression of PTEN and IP3R3 was assessed by immunohistochemistry using eight available tissue microarrays (TMAs) and one commercially available TMA. The eight TMAs were built generating triplicate cores from radical prostatectomy cases as previously described23, and included 89 prostate adenocarcinomas. The commercially available TMA was from USBiomax and included 60 prostate adenocarcinomas. Five-micrometre sections were deparaffinized and subjected to standard avidin-biotin-based immunohistochemistry procedures as reported in ref. 24. Primary antibodies were anti-PTEN (rabbit monoclonal, Cell Signaling Technology, no. 9559, 1:200 dilution) and anti-IP3R3 (rabbit polyclonal, Bethyl Laboratories, Inc., no. IHC-00639, 1:500 dilution). TMAs were scored by determining the percentage of epithelial prostate cells with immunoreactivity (0 = no expression, 1 = mild/ moderate expression, 2 = high and very high expression) for the protein of interest per tissue core. A score was generated for each tissue core by multiplying the percentage of expression by the intensity of expression. The average values of the representative cores from each patient sample were obtained and the median was used as a cut-off to transform protein expression into a qualitative variable. Cases were classified into three categories: ‘negative’ when score was 0, ‘low expression when score was lower than the median and ‘high expression when score was higher than the median. Linear regression analysis was performed with the GraphPad Prism 7.02 software with χ2 test. Original data are presented in Source Data for Fig. 2d.
Live-cell imaging
HeLa cells were grown in dishes with a glass base (Thermo Scientific no. 150682) in DMEM medium supplemented with 10% FBS. Cells were transfected with GFP-FBXL2 cDNA using Lipofactemine 3000 reagent. Two hours post-transfection, cells were incubated in fresh medium containing GGTi-2418 (15 μM) for 16 h at 37 °C supplemented with 5% CO2. Live-cell imaging was carried out with a Zeiss LSM-510 META confocal microscope using a 63× oil-based objective in an incubation chamber at 37 °C supplemented with 5% CO2. Images were captured and processed with ZEN/ZEN lite imaging software from Zeiss.
CRISPR genome editing
To generate ITPR3 Q550A;F553A;R554A, an optimal gRNA target sequence closest to the genomic target site and a 2 kb homologous recombination (HR) donor template were designed using the Benchling CRISPR Genome Engineering tool. The HR donor template was designed to introduce alanine substitutions at position Q550, F553 and R554, silent base-pair mutations to disrupt the PAM site, and an XhoI restriction site for bulk population screening, and was purchased as a synthetic gene from IDT. ITPR3 gRNA target sequence (see Extended Data Fig. 7a) was cloned into pSpCas9(BB)-2A-GFP (PX458), a gift from F. Zhang (Addgene plasmid no. 48138). Similarly, to generate FBXL2 deletions, two optimal gRNA target sequences (see Extended Data Fig. 1f) closest to the genomic target sites in either exon 2 or exon 3 were designed using the Benchling CRISPR Genome Engineering tool and cloned into the pSpCas9(BB)-2A-GFP (PX458) (ref. 25). RPE-1, A549 and PC3 cells were seeded into 10-cm dishes at approximately 70% confluency, and transfected with 5 μg of gRNA-containing PX458 plasmid and HR donor template, using lipofectamine 3000 (Life Technologies). The transfection was performed according to the manufacturer's recommended protocol, using a 2:1 ratio of lipofectamine:DNA. Two days after transfection, GFP-positive cells were sorted using the Beckman Coulter MoFlo XDP cell sorter (100 μm nozzle), and 15,000 cells were plated on a 15 cm dish. For ITPR3 Q550A;F553A;R554A knock-in, a GFP-sorted population sample was also collected for subsequent bulk population genotyping by amplification of the target region and digestion with XhoI. 8–10 days later, single cell clones were picked, trypsinized in 0.25% Trypsin-EDTA for 5 min, and plated into individual wells of a 96-well plate for genotyping. Genomic DNA was collected using QuickExtract (Epicentre). Genotyping PCRs were performed with MangoTaq DNA Polymerase (Bioline), using primers surrounding the genomic target sites (see Extended Data Fig. 1f and Extended Data Fig. 7a). The resulting PCR products were then purified. For ITPR3 Q550A;F553A;R554A knock-in, PCR products were also digested with XhoI. Positive clones were sequenced to determine the presence of a indel event (FBXL2 knockout) or complete recombination event (ITPR3 Q550A;F553A;R554A knock-in). To further validate the mutational status of candidate clones, the PCR products were subjected to TOPO-TA Cloning (Invitrogen), and sequenced in order to distinguish the amplified products of distinct alleles. Fifty bacterial colonies for each TOPO-TA cloning reaction were sequenced and aligned to the corresponding wild-type template in Benchling to confirm that all alleles were correctly targeted.
Statistics analyses
All data were analysed by Prism 6 (GraphPad). Unless otherwise noted in figure legends, data are representative of at least three biologically independent experiments. Two-group datasets were analysed by Student's unpaired t-test. For three or more group analysis, one-way ANOVA Tukey's multiple comparison test was used. Linear regression analysis was performed with the GraphPad Prism 7.02 software χ2 test. One asterisk was used for P < 0.05, two asterisks for P < 0.01, three asterisks for P < 0.001, and four asterisks for P < 0.0001. Statistical analyses from independent experiments are reported in the Source Data files and in Supplementary Table 1.
Data availability
Most data generated or analysed during this study are included in this published article and its supplementary information files. Additional datasets generated during and/or analysed during the current study and relevant information are available from the corresponding authors upon reasonable request.
Extended Data
Supplementary Material
Acknowledgments
The authors thank W. Dai, R. Parsons, M. Phillips and K. Tanaka for reagents; E. DeMarchi, C. Espiritu, G. Rona and E. Schenkein for their contribution to this study, and L. Cantley and B. Neel for advice. M.P. and P. P. are grateful to T. M. Thor and C. degli. Scrovegni, respectively, for continuous support. This work was funded by grants from the NIH to MP, and grants from AIRC (IG-18624 and MFAG-13521), funds from Ferrara's University (5x1000), the Italian Ministry of Health, and Cariplo to S.M., C.G. and P. P. A.S., L.F. and M.P.W. are supported by the Stowers Institute for Medical Research. M.P. is an Investigator with the Howard Hughes Medical Institute.
Footnotes
Supplementary Information is available in the online version of the paper.
Author Contributions: S.K. and C.G. planned and performed most experiments and helped to write the manuscript. D.S. generated the CRISPR knock-in and heterozygous clones. M.P. directed and coordinated the study, oversaw all results, and wrote the manuscript. P. P. supervised the study and oversaw the results. A.L., M.M. and C.C. performed immunohistochemical analysis. S.S. provided advice for the in vivo experiments. A.S., L.F. and M.W. performed the mass spectrometry analysis. J.P. and S.M. helped with some experiments. All authors discussed the results and commented on the manuscript.
The authors declare competing financial interests: details are available in the online version of the paper.
References
- 1.Wright FA, Wojcikiewicz RJ. Chapter 4 - inositol 1,4,5-trisphosphate receptor ubiquitination. Prog Mol Biol Transl Sci. 2016;141:141–159. doi: 10.1016/bs.pmbts.2016.02.004. [DOI] [PubMed] [Google Scholar]
- 2.Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552–565. doi: 10.1038/nrm1150. [DOI] [PubMed] [Google Scholar]
- 3.Skaar JR, Pagan JK, Pagano M. Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol. 2013;14:369–381. doi: 10.1038/nrm3582. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011;11:289–301. doi: 10.1038/nrc3037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004;5:497–508. doi: 10.1016/S1470-2045(04)01529-3. [DOI] [PubMed] [Google Scholar]
- 6.Giorgi C, et al. Intravital imaging reveals p53-dependent cancer cell death induced by phototherapy via calcium signaling. Oncotarget. 2015;6:1435–1445. doi: 10.18632/oncotarget.2935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Kazi A, et al. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Mol Cell Biol. 2009;29:2254–2263. doi: 10.1128/MCB.01029-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Wang C, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell. 2005;18:425–434. doi: 10.1016/j.molcel.2005.04.004. [DOI] [PubMed] [Google Scholar]
- 9.Kuchay S, et al. FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade. Nat Cell Biol. 2013;15:472–480. doi: 10.1038/ncb2731. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Deshaies RJ. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 2014;12:94. doi: 10.1186/s12915-014-0094-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Clapham DE. Calcium signaling. Cell. 2007;131:1047–1058. doi: 10.1016/j.cell.2007.11.028. [DOI] [PubMed] [Google Scholar]
- 12.Bittremieux M, Parys JB, Pinton P, Bultynck G. ER functions of oncogenes and tumor suppressors: Modulators of intracellular Ca(2+) signaling. Biochim Biophys Acta. 2016;1863(6 Pt B):1364–1378. doi: 10.1016/j.bbamcr.2016.01.002. [DOI] [PubMed] [Google Scholar]
- 13.Puc J, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005;7:193–204. doi: 10.1016/j.ccr.2005.01.009. [DOI] [PubMed] [Google Scholar]
- 14.D'Angiolella V, et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell. 2012;149:1023–1034. doi: 10.1016/j.cell.2012.03.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Duan S, et al. mTOR generates an auto-amplification loop by triggering the 3TrCP- and CK1α-dependent degradation of DEPTOR. Mol Cell. 2011;44:317–324. doi: 10.1016/j.molcel.2011.09.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Duan S, et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature. 2012;481:90–93. doi: 10.1038/nature10688. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Dankert JF, et al. Cyclin F-mediated degradation of SLBP limits H2A.X accumulation and apoptosis upon genotoxic stress in G2. Mol Cell. 2016;64:507–519. doi: 10.1016/j.molcel.2016.09.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Yoshida Y, et al. A comprehensive method for detecting ubiquitinated substrates using TR-TUBE. Proc Natl Acad Sci USA. 2015;112:4630–4635. doi: 10.1073/pnas.1422313112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440–3450. [PubMed] [Google Scholar]
- 20.Marchi S, et al. Akt kinase reducing endoplasmic reticulum Ca2+ release protects cells from Ca2+-dependent apoptotic stimuli. Biochem Biophys Res Commun. 2008;375:501–505. doi: 10.1016/j.bbrc.2008.07.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Bonora M, et al. Subcellular calcium measurements in mammalian cells using jellyfish photoprotein aequorin-based probes. Nat Protoc. 2013;8:2105–2118. doi: 10.1038/nprot.2013.127. [DOI] [PubMed] [Google Scholar]
- 22.Wieckowski MR, Giorgi C, Lebiedzinska M, Duszynski J, Pinton P. Isolation of mitochondria-associated membranes and mitochondria from animal tissues and cells. Nat Protocols. 2009;4:1582–1590. doi: 10.1038/nprot.2009.151. [DOI] [PubMed] [Google Scholar]
- 23.Barber AG, et al. Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PLoS One. 2014;9:e98786. doi: 10.1371/journal.pone.0098786. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Castillo-Martin M, Thin TH, Collazo Lorduy A, Cordon-Cardo C. Immunopathologic assessment of PTEN expression. Methods Mol Biol. 2016;1388:23–37. doi: 10.1007/978-1-4939-3299-3_3. [DOI] [PubMed] [Google Scholar]
- 25.Ran FA, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protocols. 2013;8:2281–2308. doi: 10.1038/nprot.2013.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Bokkala S, Joseph SK. Angiotensin II-induced down-regulation of inositol trisphosphate receptors in WB rat liver epithelial cells. Evidence for involvement of the proteasome pathway. J Biol Chem. 1997;272:12454–12461. doi: 10.1074/jbc.272.19.12454. [DOI] [PubMed] [Google Scholar]
- 27.Oberdorf J, Webster JM, Zhu CC, Luo SG, Wojcikiewicz RJ. Down-regulation of types I, II and III inositol 1,4,5-trisphosphate receptors is mediated by the ubiquitin/proteasome pathway. Biochem J. 1999;339:453–461. [PMC free article] [PubMed] [Google Scholar]
- 28.Alzayady KJ, Panning MM, Kelley GG, Wojcikiewicz RJ. Involvement of the p97-Ufd1-Npl4 complex in the regulated endoplasmic reticulum-associated degradation of inositol 1,4,5-trisphosphate receptors. J Biol Chem. 2005;280:34530–34537. doi: 10.1074/jbc.M508890200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Mikoshiba K. IP3 receptor/Ca2+ channel: from discovery to new signaling concepts. J Neurochem. 2007;102:1426–1446. doi: 10.1111/j.1471-4159.2007.04825.x. [DOI] [PubMed] [Google Scholar]
- 30.Lin CC, Baek K, Lu Z. Apo and InsP3-bound crystal structures of the ligand-binding domain of an InsP3 receptor. Nat Struct Mol Biol. 2011;18:1172–1174. doi: 10.1038/nsmb.2112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Seo MD, et al. Structural and functional conservation of key domains in InsP3 and ryanodine receptors. Nature. 2012;483:108–112. doi: 10.1038/nature10751. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Fan G, et al. Gating machinery of InsP3R channels revealed by electron cryomicroscopy. Nature. 2015;527:336–341. doi: 10.1038/nature15249. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Giorgi C, et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science. 2010;330:1247–1251. doi: 10.1126/science.1189157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Marchi S, et al. Selective modulation of subtype III IP3R by Akt regulates ER Ca2+ release and apoptosis. Cell Death Dis. 2012;3:e304. doi: 10.1038/cddis.2012.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Giorgi C, Bonora M, Pinton P. Inside the tumor: p53 modulates calcium homeostasis. Cell Cycle. 2015;14:933–934. doi: 10.1080/15384101.2015.1010973. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Oakes SA, et al. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci USA. 2005;102:105–110. doi: 10.1073/pnas.0408352102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Sung PJ, et al. Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors. Proc Natl Acad Sci USA. 2013;110:20593–20598. doi: 10.1073/pnas.1306431110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Chen R, et al. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate. J Cell Biol. 2004;166:193–203. doi: 10.1083/jcb.200309146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Khan MT, Wagner L, II, Yule DI, Bhanumathy C, Joseph SK. Akt kinase phosphorylation of inositol 1,4,5-trisphosphate receptors. J Biol Chem. 2006;281:3731–3737. doi: 10.1074/jbc.M509262200. [DOI] [PubMed] [Google Scholar]
- 40.Bononi A, et al. Identification of PTEN at the ER and MAMs and its regulation of Ca(2+) signaling and apoptosis in a protein phosphatase-dependent manner. Cell Death Difer. 2013;20:1631–1643. doi: 10.1038/cdd.2013.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Tan MK, Lim HJ, Bennett EJ, Shi Y, Harper JW. Parallel SCF adaptor capture proteomics reveals a role for SCFFBXL17 in NRF2 activation via BACH1 repressor turnover. Mol Cell. 2013;52:9–24. doi: 10.1016/j.molcel.2013.08.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Alzayady KJ, et al. Functional inositol 1,4,5-trisphosphate receptors assembled from concatenated homo- and heteromeric subunits. J Biol Chem. 2013;288:29772–29784. doi: 10.1074/jbc.M113.502203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Wojcikiewicz RJ, He Y. Type I, II and III inositol 1,4,5-trisphosphate receptor co-immunoprecipitation as evidence for the existence of heterotetrameric receptor complexes. Biochem Biophys Res Commun. 1995;213:334–341. doi: 10.1006/bbrc.1995.2134. [DOI] [PubMed] [Google Scholar]
- 44.Joseph SK, Lin C, Pierson S, Thomas AP, Maranto AR. Heteroligomers of type-I and type-III inositol trisphosphate receptors in WB rat liver epithelial cells. J Biol Chem. 1995;270:23310–23316. doi: 10.1074/jbc.270.40.23310. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Most data generated or analysed during this study are included in this published article and its supplementary information files. Additional datasets generated during and/or analysed during the current study and relevant information are available from the corresponding authors upon reasonable request.